RxDoctor Payments Data

Eric Mitchnick, MD

Urology · Port Jefferson Station, NYNPI 1043254469

Payments from drug & device makers

$24,903in general payments, 2019–2025

Across 673 payments — averaging $37.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$8K
  • Johnson & Johnson$3K
  • Astellas Pharma US Inc$2K
  • Bayer$2K
  • Sumitomo Pharma America, Inc.$1K
  • Endo Pharmaceuticals Inc.$1K
  • plus $8K from 38 others

What the payments were for

  • Consulting fees$1501%
  • Speaking & faculty fees$6,07624%
  • Travel & lodging$390%
  • Food & beverage$17,76071%
  • Education$8784%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,903 in reported general payments places this provider in the 80th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$1,794,832
Medicare patients
2,068
Services billed
700,768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide27$487,437
ErleadaApalutamide12$181,804
MyrbetriqMirabegron208$146,334
Abiraterone Acetate34$117,045
GemtesaVibegron148$110,828
Tamsulosin Hcl1,611$30,705
Testosterone28$25,473
Mirabegron ErMirabegron31$23,169
Alfuzosin Hcl ErAlfuzosin Hcl898$16,631
Silodosin129$16,187
Solifenacin Succinate120$14,789
Finasteride890$12,777
Methenamine Hippurate169$12,479
NitrofurantoinNitrofurantoin Macrocrystal218$9,058
Oxybutynin Chloride ErOxybutynin Chloride256$6,686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,888$633,772235 claims
Johnson & JohnsonErleada$2,544$181,80412 claims
Sumitomo Pharma America, Inc.Gemtesa$1,189$110,828148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 952 urology providers in New York.

Other urology in Port Jefferson Station

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →